| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $359,010 | 7 | 100 |
Sells | $0 | 0 | 0 |
| Williamson Robert F III | director | 3 | $152,097 | 0 | $0 | $152,097 |
| Graham Juan | Chief Financial Officer | 1 | $74,946 | 0 | $0 | $74,946 |
| Spoor Johan M. | Chief Executive Officer | 1 | $59,673 | 0 | $0 | $59,673 |
| Woods Lori A | director | 1 | $49,999 | 0 | $0 | $49,999 |
| Hunt Jonathan Robert | Chief Accounting Officer | 1 | $22,295 | 0 | $0 | $22,295 |
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Over the last 12 months, insiders at Perspective Therapeutics, Inc. have bought $359,010 and sold $0 worth of Perspective Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Perspective Therapeutics, Inc. have bought $29.4M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Williamson Robert F III (director) — $152,097. Graham Juan (Chief Financial Officer) — $74,946. Spoor Johan M. (Chief Executive Officer) — $59,673.
The last purchase of 11,000 shares for transaction amount of $22,295 was made by Hunt Jonathan Robert (Chief Accounting Officer) on 2025‑11‑13.
| 2025-11-13 | Hunt Jonathan Robert | Chief Accounting Officer | 11,000 0.0147% | $2.03 | $22,295 | +22.71% | ||
| 2025-11-12 | Williamson Robert F III | director | 9,498 0.0123% | $2.10 | $19,946 | +19.34% | ||
| 2025-03-31 | Woods Lori A | director | 23,475 0.0317% | $2.13 | $49,999 | +40.38% | ||
| 2025-03-31 | Williamson Robert F III | director | 38,145 0.0518% | $2.14 | $81,775 | +40.38% | ||
| 2025-03-28 | Williamson Robert F III | director | 22,192 0.0339% | $2.27 | $50,376 | +33.41% | ||
| 2025-03-28 | Spoor Johan M. | Chief Executive Officer | 26,676 0.0401% | $2.24 | $59,673 | +33.41% | ||
| 2025-03-28 | Graham Juan | Chief Financial Officer | 33,333 0.0504% | $2.25 | $74,946 | +33.41% | ||
| 2024-12-04 | Spoor Johan M. | CEO | 8,000 0.0119% | $3.77 | $30,132 | -14.02% | ||
| 2024-12-04 | HENSON HEIDI | director | 25,975 0.0396% | $3.85 | $100,004 | -14.02% | ||
| 2024-11-25 | Williamson Robert F III | director | 6,266 0.0078% | $3.64 | $22,814 | -12.33% | ||
| 2024-11-25 | Spoor Johan M. | CEO | 26,500 0.0342% | $3.79 | $100,468 | -12.33% | ||
| 2024-11-25 | Hunt Jonathan Robert | Chief Financial Officer | 12,829 0.0167% | $3.82 | $48,974 | -12.33% | ||
| 2024-06-17 | Hunt Jonathan Robert | Chief Financial Officer | 1,800 0.006% | $9.81 | $17,667 | -64.80% | ||
| 2024-06-14 | Woods Lori A | director | 4,587 0.017% | $10.90 | $49,990 | -65.79% | ||
| 2024-06-13 | Spoor Johan M. | CEO | 100,000 0.0399% | $1.17 | $117,430 | -68.32% | ||
| 2024-06-03 | Woods Lori A | director | 34,246 0.017% | $1.46 | $49,992 | -71.42% | ||
| 2024-05-31 | Williamson Robert F III | director | 55,000 0.0258% | $1.38 | $75,900 | -70.94% | ||
| 2024-05-31 | Hunt Jonathan Robert | Chief Financial Officer | 25,006 0.0119% | $1.40 | $35,007 | -70.94% | ||
| 2024-05-29 | Williamson Robert F III | director | 30,031 0.0136% | $1.33 | $40,014 | -69.37% | ||
| 2024-03-06 | Lantheus Alpha Therapy, LLC | 10 percent owner | 60.43M 19.5267% | $0.95 | $57.41M | +18.53% |
| Woods Lori A | director | 183460 0.2468% | $427,461.80 | 3 | 0 | <0.0001% |
| Hunt Jonathan Robert | Chief Accounting Officer | 59800 0.0804% | $139,334.00 | 4 | 0 | <0.0001% |
| Spoor Johan M. | Chief Executive Officer | 59383 0.0799% | $138,362.39 | 4 | 0 | <0.0001% |
| Graham Juan | Chief Financial Officer | 35354 0.0476% | $82,374.82 | 1 | 0 | |
| Williamson Robert F III | director | 9864 0.0133% | $22,983.12 | 11 | 0 | +45.52% |
| Lantheus Alpha Therapy, LLC | 10 percent owner | 116773394 157.0844% | $272.08M | 1 | 0 | +18.53% |
| Puhlmann Markus | Chief Medical Officer | 1375425 1.8502% | $3.2M | 1 | 0 | +147.24% |
| HENSON HEIDI | director | 25975 0.0349% | $60,521.75 | 1 | 0 | <0.0001% |
$1,105,104 | 34 | -11.40% | $435.81M | |
Perspective Therapeutics, Inc. (CATX) | $58,432,429 | 19 | 7.16% | $173.21M |
$5,181,911 | 18 | -5.82% | $75.03M | |
$12,684,208 | 6 | 17.63% | $14.3M | |
$170,016 | 6 | 9.19% | $182.53M | |
$24,971 | 6 | -37.72% | $47.87M | |
$6,864 | 5 | 59.01% | $12.87M | |
$91,060 | 5 | -48.15% | $12.62M | |
$21,637 | 4 | -55.86% | $3.2M | |
$2,000,000 | 1 | -13.69% | $1.15B | |
$13,650 | 1 | -48.97% | $8.55M | |
$19,977 | 1 | 10.97% | $284.3M |
| Increased Positions | 49 | +45.79% | 7M | +15.71% |
| Decreased Positions | 40 | -37.38% | 5M | -12.88% |
| New Positions | 16 | New | 1M | New |
| Sold Out Positions | 12 | Sold Out | 1M | Sold Out |
| Total Postitions | 116 | +8.41% | 43M | +2.83% |
| Fmr Llc | $27,930.00 | 13.53% | 10.01M | -1M | -9.84% | 2025-09-30 |
| Blackrock, Inc. | $12,183.00 | 5.9% | 4.37M | +72,426 | +1.69% | 2025-09-30 |
| Vanguard Group Inc | $9,592.00 | 4.65% | 3.44M | +163,532 | +4.99% | 2025-09-30 |
| Avidity Partners Management Lp | $8,353.00 | 4.05% | 2.99M | +1M | +61.09% | 2025-09-30 |
| Morgan Stanley | $7,703.00 | 3.73% | 2.76M | +1M | +70.07% | 2025-09-30 |
| Millennium Management Llc | $7,146.00 | 3.46% | 2.56M | -32,487 | -1.25% | 2025-09-30 |
| Nicholson Wealth Management Group, Llc | $4,515.00 | 2.19% | 1.62M | +4,010 | +0.25% | 2025-09-30 |
| Geode Capital Management, Llc | $3,997.00 | 1.94% | 1.43M | +49,673 | +3.59% | 2025-09-30 |
| Nuveen, Llc | $3,651.00 | 1.77% | 1.31M | -988,672 | -43.04% | 2025-09-30 |
| State Street Corp | $3,082.00 | 1.49% | 1.1M | +15,851 | +1.46% | 2025-09-30 |